These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3603632)

  • 1. The efficacy of meningococcal polysaccharide vaccine in preventing group A meningococcal disease in The Gambia, West Africa.
    Greenwood BM; Smith AW; Hassan-King M; Bijlmer HA; Shenton FC; Hughes AS; Nunn PP; Jack AD; Gowers PR
    Trans R Soc Trop Med Hyg; 1986; 80(6):1006-7. PubMed ID: 3603632
    [No Abstract]   [Full Text] [Related]  

  • 2. Emergency vaccination against epidemic meningitis in Ghana: implications for the control of meningococcal disease in West Africa.
    Woods CW; Armstrong G; Sackey SO; Tetteh C; Bugri S; Perkins BA; Rosenstein NE
    Lancet; 2000 Jan; 355(9197):30-3. PubMed ID: 10615888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Love's labours lost": failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa.
    Robbins JB; Towne DW; Gotschlich EC; Schneerson R
    Lancet; 1997 Sep; 350(9081):880-2. PubMed ID: 9310615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Observation on the epidemiologic efficacy for 9 years on epidemic meningococcal polysaccharide vaccine of group A by district immunization method].
    Ma Z
    Zhonghua Liu Xing Bing Xue Za Zhi; 1991 Apr; 12(2):69-71. PubMed ID: 2065343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine.
    Reingold AL; Broome CV; Hightower AW; Ajello GW; Bolan GA; Adamsbaum C; Jones EE; Phillips C; Tiendrebeogo H; Yada A
    Lancet; 1985 Jul; 2(8447):114-8. PubMed ID: 2862316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meningococcal meningitis in sub-Saharan Africa: the case for mass and routine vaccination with available polysaccharide vaccines.
    Robbins JB; Schneerson R; Gotschlich EC; Mohammed I; Nasidi A; Chippaux JP; Bernardino L; Maiga MA
    Bull World Health Organ; 2003; 81(10):745-50; discussion 751-5. PubMed ID: 14758435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospects and challenges with introduction of a mono-valent meningococcal conjugate vaccine in Africa.
    Okoko BJ; Idoko OT; Adegbola RA
    Vaccine; 2009 Mar; 27(14):2023-9. PubMed ID: 19095025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status--meningococcal vaccine.
    Merchant R; Divekar R
    Indian J Pediatr; 1988; 55(2):256-60. PubMed ID: 3042624
    [No Abstract]   [Full Text] [Related]  

  • 9. Meningococcal meningitis: vaccination outbreak response and epidemiological changes in the African meningitis belt.
    Carod Artal FJ
    Int Health; 2015 Jul; 7(4):226-7. PubMed ID: 25878213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Meningococcal meningitis: preliminary epidemiological results on the introduction of a prophylactic vaccine].
    Galli MG
    G Batteriol Virol Immunol; 1982; 75(7-12):251-4. PubMed ID: 7188258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine for meningococcal meningitis tested.
    Marwick C
    JAMA; 1991 Oct; 266(15):2052-3. PubMed ID: 1920685
    [No Abstract]   [Full Text] [Related]  

  • 12. Technical Development of a New Meningococcal Conjugate Vaccine.
    Frasch CE; Kapre SV; Lee CH; Préaud JM
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S404-9. PubMed ID: 26553667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy.
    MacLennan J; Obaro S; Deeks J; Lake D; Elie C; Carlone G; Moxon ER; Greenwood B
    J Infect Dis; 2001 Jan; 183(1):97-104. PubMed ID: 11087205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Survey on efficacy of inoculating purified polysaccharide vaccines as an emergency measure in preventing epidemic meningitis].
    Xu CH
    Zhonghua Liu Xing Bing Xue Za Zhi; 1982 Dec; 3(6):328-30. PubMed ID: 6821030
    [No Abstract]   [Full Text] [Related]  

  • 15. [Vaccination against A-C meningococcal meningitis: ethics and management].
    Fernández Fraga C
    Aten Primaria; 1998 Apr; 21(7):502, 504. PubMed ID: 9656594
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effectiveness of an immunization campaign with group A and C meningococcal polysaccharide vaccine in controlling an outbreak of group C meningococcal disease].
    Gong J; Li CY; Dong BQ; Huang JZ; Quan Y; Lu WZ; Luo CH; Mao WC; Liao HZ; Fang JS; Cui XL; Xie GL; Wu XH; Lan RW
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):552-5. PubMed ID: 19040035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fast-tracking meningococcal vaccination.
    Fairley CK; White JM; Begg NT
    Lancet; 1994 Oct; 344(8930):1164-5. PubMed ID: 7934525
    [No Abstract]   [Full Text] [Related]  

  • 18. [Preventive effectiveness of an urgent mass vaccination with purified meningococcal polysaccharide vaccine observed during a meningitis epidemic].
    Wu C
    Zhonghua Liu Xing Bing Xue Za Zhi; 1985 Dec; 6(6):344-6. PubMed ID: 3938683
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety of group C meningococcal vaccine.
    Commun Dis Rep CDR Wkly; 2000 Sep; 10(35):311, 314. PubMed ID: 10992627
    [No Abstract]   [Full Text] [Related]  

  • 20. Conjugate vaccines for preventing meningococcal C meningitis and septicaemia.
    Conterno LO; Silva Filho CR; Rüggeberg JU; Heath PT
    Cochrane Database Syst Rev; 2006 Jul; (3):CD001834. PubMed ID: 16855979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.